Compare JVA & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | NNVC |
|---|---|---|
| Founded | 1971 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 22.2M |
| IPO Year | 1997 | 2008 |
| Metric | JVA | NNVC |
|---|---|---|
| Price | $3.16 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.6K | ★ 253.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $90,655,294.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.48 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.76 | $0.85 |
| 52 Week High | $5.62 | $2.23 |
| Indicator | JVA | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 61.45 |
| Support Level | $2.93 | $1.11 |
| Resistance Level | $3.25 | $1.52 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 53.12 | 71.72 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.